Literature DB >> 8918554

Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme.

J L McKimm-Breschkin1, M McDonald, T J Blick, P M Colman.   

Abstract

We previously isolated a variant of the influenza virus NWS/G70C, with a decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en in vitro, which has a mutation in one of the conserved residues of the neuraminidase Glu 119 to Gly. Despite the mutation, purified neuraminidase demonstrated the same specific activity as the parent neuraminidase. In contrast, characterization of a similar mutant by another group revealed a low specific activity of the enzyme. We confirm here that the specific activity of our variant is the same as that of the parent, but report that this mutation makes the enzyme inherently unstable, at high and low temperatures, either on the virion or as purified neuraminidase. Thus, for a valid determination of specific activity the concentration of native NA needs to be determined at the time of enzyme assay. Structurally, the instability may be partially explained by the introduction of a side chain (Gly), which carries a greater entropy penalty in condensation of the structure from the unfolded to the folded state and this, together with the loss of stabilizing interaction between Glu 119 and its neighbors in the active site, is not compensated for by the water molecule occupying the position of the carboxylate group (6).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8918554     DOI: 10.1006/viro.1996.0595

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses.

Authors:  Hui-Ling Yen; Erich Hoffmann; Garry Taylor; Christoph Scholtissek; Arnold S Monto; Robert G Webster; Elena A Govorkova
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.

Authors:  Jennifer L McKimm-Breschkin; Janelle Williams; Susan Barrett; Kim Jachno; Mandy McDonald; Peter G Mohr; Takehiko Saito; Masato Tashiro
Journal:  J Antimicrob Chemother       Date:  2013-06-11       Impact factor: 5.790

3.  Detection of an influenza B virus strain with reduced susceptibility to neuraminidase inhibitor drugs.

Authors:  Nathalie Bastien; Jonathan B Gubbay; David Richardson; Katrina Sleeman; Larisa Gubareva; Yan Li
Journal:  J Clin Microbiol       Date:  2011-09-07       Impact factor: 5.948

4.  Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor.

Authors:  Shuji Hatakeyama; Yuko Sakai-Tagawa; Maki Kiso; Hideo Goto; Chiharu Kawakami; Keiko Mitamura; Norio Sugaya; Yasuo Suzuki; Yoshihiro Kawaoka
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

Review 5.  Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

Authors:  Jennifer L McKimm-Breschkin
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

6.  Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.

Authors:  Michael Z Wang; Chun Y Tai; Dirk B Mendel
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

7.  Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en.

Authors:  L V Gubareva; M J Robinson; R C Bethell; R G Webster
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

8.  The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA.

Authors:  O Greengard; N Poltoratskaia; E Leikina; J Zimmerberg; A Moscona
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071.

Authors:  C Y Tai; P A Escarpe; R W Sidwell; M A Williams; W Lew; H Wu; C U Kim; D B Mendel
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

Authors:  J McKimm-Breschkin; T Trivedi; A Hampson; A Hay; A Klimov; M Tashiro; F Hayden; M Zambon
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.